Insider Trading activities of Ra Pharmaceuticals, Inc. (RARX)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Ra Pharmaceuticals, Inc. (RARX) since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Ra Pharmaceuticals, Inc. since year 2005. Table 2 shows the detailed insider transactions of Ra Pharmaceuticals, Inc. since 2005. The reporting company's ticker symbol is RARX. The reporting company's CIK number is 1481512.
The total value of stock buying since 2005 is $132,247,045.
The total value of stock sales since 2005 is $10,239,257.
The total value of stock option exercises since 2005 is $440,155.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Ra Pharmaceuticals, Inc. (RARX).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2019-10 0 $0 22,880 $1,072,206 20,595 $88,031
2019-09 0 $0 20,595 $521,722 20,595 $88,031
2019-08 0 $0 22,880 $635,663 20,595 $88,031
2019-07 0 $0 20,595 $680,471 20,595 $88,031
2019-06 0 $0 23,452 $524,468 20,595 $88,031
2019-04 0 $0 0 $0 15,329 $0
2019-02 0 $0 0 $0 50,835 $0
2018-12 2,658,065 $41,200,007 0 $0 0 $0
2018-02 5,000,000 $30,000,000 0 $0 0 $0
2017-06 0 $0 99,603 $2,206,303 0 $0
2017-05 0 $0 109,977 $2,755,472 0 $0
2017-03 0 $0 7,778 $162,661 0 $0
2017-02 0 $0 76,837 $1,610,494 0 $0
2016-10 4,695,926 $61,047,038 5,369 $69,797 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Ra Pharmaceuticals, Inc. insiders (RARX)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2019-10-17 Ricardo Alonso (See Remarks) Sale 2,285 46.70 106,709
2019-10-16 Read Simon (Chief Scientific Officer) Sale 10,000 46.87 468,730
2019-10-16 Read Simon (Chief Scientific Officer) Option Ex 10,000 2.87 28,700
2019-10-15 Farzaneh-far Ramin (Chief Medical Officer) Sale 10,595 46.89 496,767
2019-10-15 Farzaneh-far Ramin (Chief Medical Officer) Option Ex 10,595 5.60 59,331
2019-09-16 Farzaneh-far Ramin (Chief Medical Officer) Sale 10,595 25.26 267,672
2019-09-16 Farzaneh-far Ramin (Chief Medical Officer) Option Ex 10,595 5.60 59,331
2019-09-12 Read Simon (Chief Scientific Officer) Sale 10,000 25.41 254,050
2019-09-12 Read Simon (Chief Scientific Officer) Option Ex 10,000 2.87 28,700
2019-08-23 Ricardo Alonso (See Remarks) Sale 2,285 27.89 63,740
2019-08-23 Read Simon (Chief Scientific Officer) Sale 10,000 27.77 277,700
2019-08-23 Read Simon (Chief Scientific Officer) Option Ex 10,000 2.87 28,700
2019-08-23 Farzaneh-far Ramin (Chief Medical Officer) Sale 10,595 27.77 294,223
2019-08-23 Farzaneh-far Ramin (Chief Medical Officer) Option Ex 10,595 5.60 59,331
2019-07-17 Read Simon (Chief Scientific Officer) Sale 10,000 32.95 329,480
2019-07-17 Read Simon (Chief Scientific Officer) Option Ex 10,000 2.87 28,700
2019-07-15 Farzaneh-far Ramin (Chief Medical Officer) Sale 10,595 33.13 350,991
2019-07-15 Farzaneh-far Ramin (Chief Medical Officer) Option Ex 10,595 5.60 59,331
2019-06-21 Ricardo Alonso (See Remarks) Sale 2,857 23.73 67,782
2019-06-18 Read Simon (Chief Scientific Officer) Sale 10,000 22.65 226,500
2019-06-18 Read Simon (Chief Scientific Officer) Option Ex 10,000 2.87 28,700
2019-06-17 Farzaneh-far Ramin (Chief Medical Officer) Sale 10,595 21.73 230,186
2019-06-17 Farzaneh-far Ramin (Chief Medical Officer) Option Ex 10,595 5.60 59,331
2019-04-16 King John C (Chief Commercial Officer) Option Ex 15,329 .00 0
2019-02-01 Read Simon (Chief Scientific Officer) Option Ex 9,167 .00 0
2019-02-01 Farzaneh-far Ramin (Chief Medical Officer) Option Ex 10,417 .00 0
2019-02-01 Treco Douglas A (President and CEO) Option Ex 20,834 .00 0
2019-02-01 Lubner David Charles (Executive V.P. & CFO) Option Ex 10,417 .00 0
2018-12-14 Shah Rajeev M. Buy 1,006,452 15.50 15,600,006
2018-12-14 Sandell Scott D (10% Owner) Buy 645,161 15.50 9,999,995
2018-12-12 Kolchinsky Peter Buy 1,006,452 15.50 15,600,006
2018-02-14 Shah Rajeev M. Buy 2,500,000 6.00 15,000,000
2018-02-14 Kolchinsky Peter Buy 2,500,000 6.00 15,000,000
2017-06-19 Novartis Ag (10% Owner) Sale 3,220 22.02 70,897
2017-06-16 Novartis Ag (10% Owner) Sale 53,200 21.25 1,130,234
2017-06-08 Novartis Ag (10% Owner) Sale 700 22.00 15,400
2017-06-07 Novartis Ag (10% Owner) Sale 4,840 22.11 106,997
2017-06-06 Novartis Ag (10% Owner) Sale 7,274 22.98 167,163
2017-06-05 Novartis Ag (10% Owner) Sale 4,780 23.11 110,489
2017-06-02 Novartis Ag (10% Owner) Sale 14,867 23.47 348,943
2017-06-01 Novartis Ag (10% Owner) Sale 10,722 23.89 256,180
2017-05-31 Novartis Ag (10% Owner) Sale 35,539 23.94 850,910
2017-05-26 Novartis Ag (10% Owner) Sale 5,300 25.14 133,268
2017-05-25 Novartis Ag (10% Owner) Sale 53 25.00 1,325
2017-05-24 Novartis Ag (10% Owner) Sale 17,451 25.00 436,362
2017-05-18 Novartis Ag (10% Owner) Sale 9,019 25.50 229,966
2017-05-17 Novartis Ag (10% Owner) Sale 22,534 25.51 574,909
2017-05-16 Novartis Ag (10% Owner) Sale 20,081 26.33 528,732
2017-03-01 Novartis Ag (10% Owner) Sale 7,778 20.91 162,661
2017-02-28 Novartis Ag (10% Owner) Sale 7,847 20.86 163,672
2017-02-27 Novartis Ag (10% Owner) Sale 57,844 20.96 1,212,294
2017-02-24 Novartis Ag (10% Owner) Sale 5,398 20.93 113,001
2017-02-23 Novartis Ag (10% Owner) Sale 4,999 21.04 105,158
2017-02-22 Novartis Ag (10% Owner) Sale 749 21.86 16,369
2016-10-31 Lettmann Jason (Director) Buy 393,923 13.00 5,120,999
2016-10-31 Lettmann Jason (Director) Sale 340 13.00 4,420
2016-10-31 Morgenthaler Management Partners Ix, Llc (10% Owner) Buy 263,538 13.00 3,425,994
2016-10-31 Morgenthaler Management Partners Ix, Llc (10% Owner) Sale 340 13.00 4,420
2016-10-31 Shah Rajeev M. (Director) Buy 161,538 13.00 2,099,994
2016-10-31 Viswanathan Ravi (10% Owner) Buy 338,462 13.00 4,400,006
2016-10-31 Viswanathan Ravi (10% Owner) Sale 435 13.00 5,655
2016-10-31 Nea 13 Gp, Ltd (10% Owner) Buy 338,462 13.00 4,400,006
2016-10-31 Nea 13 Gp, Ltd (10% Owner) Sale 435 13.00 5,655
2016-10-31 Novo A/s (10% Owner) Buy 246,154 13.00 3,200,002
2016-10-31 Kolchinsky Peter Buy 161,538 13.00 2,099,994
2016-10-31 Weller Harry R (10% Owner) Buy 338,462 13.00 4,400,006
2016-10-31 Weller Harry R (10% Owner) Sale 435 13.00 5,655
2016-10-31 Baskett Forest (10% Owner) Buy 338,462 13.00 4,400,006
2016-10-31 Baskett Forest (10% Owner) Sale 435 13.00 5,655
2016-10-31 Kolluri Krishna Kittu (10% Owner) Buy 338,462 13.00 4,400,006
2016-10-31 Kolluri Krishna Kittu (10% Owner) Sale 435 13.00 5,655
2016-10-31 Sandell Scott D (10% Owner) Buy 338,462 13.00 4,400,006
2016-10-31 Sandell Scott D (10% Owner) Sale 435 13.00 5,655
2016-10-31 Kerins Patrick J (10% Owner) Buy 338,462 13.00 4,400,006
2016-10-31 Kerins Patrick J (10% Owner) Sale 435 13.00 5,655
2016-10-31 Mott David M (10% Owner) Buy 338,462 13.00 4,400,006
2016-10-31 Mott David M (10% Owner) Sale 435 13.00 5,655
2016-10-31 Barrett M James (10% Owner) Buy 338,462 13.00 4,400,006
2016-10-31 Barrett M James (10% Owner) Sale 435 13.00 5,655
2016-10-31 Novartis Ag (10% Owner) Buy 84,615 13.00 1,099,995
2016-10-31 Novartis Ag (10% Owner) Sale 339 13.00 4,407
2016-10-31 Barris Peter J (10% Owner) Buy 338,462 13.00 4,400,006
2016-10-31 Barris Peter J (10% Owner) Sale 435 13.00 5,655

Insider trading activities including stock purchases, stock sales, and option exercises of RARX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Ra Pharmaceuticals, Inc. (symbol RARX, CIK number 1481512) see the Securities and Exchange Commission (SEC) website.




Real-time Insider Trading

Insider Officer Cluster Trading

Top Officer Buys of the Week

Top Officer Buys of the Month